Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The recent launch event of the Experimental Medicine Industry Partnership was an exciting collaboration between industry representatives and researchers from the University of Oxford. During the event, a series of workshops were held to discuss opportunities, challenges, and future directions for the application of experimental medicine in psychiatric drug development.

Business Unity and connection partnership as ropes shaped as a circle in a group of diverse strings connected together shaped as a support symbol expressing the feeling of teamwork and togetherness.

Dr Susannah Murphy, Department of Psychiatry, University of Oxford, explains:

 

'The Experimental Medicine Industry Partnership (EMIP) is a fantastic opportunity for industry partners and researchers to work together to share expertise and maximise opportunities for developing improved psychiatric treatments. By offering tailored peer review and advice the EMIP will help to rapidly progress new treatments into clinical trials, bringing potential new, life changing treatments a step closer to improving the lives of patients.'

Professor Catherine Harmer, Department of Psychiatry, University of Oxford, said:

 

'It was fascinating to hear pressing questions from an industry perspective and to take part in discussions with other academics. The conversations have spearheaded many collaborations and have inspired us to develop our models in ways that can also work for industry and their requirements. I look forward to continued and future collaborations.'

50 representatives from 15 industry partners and 90 Oxford researchers with expertise in cognitive neuroscience, pharmacology treatment, lifestyle interventions, gut health and precision psychiatry, took part in the AIMday event in July 2021, . 

Read more about this and other topics discussed during the event

For more information about the Experimental Medicine and Industry Partnership (EMIP) 

An Academic Industry Meeting Day (AIMday) is an innovative networking event that allows organisations external to the University of Oxford to set the agenda and gain academic perspective on industry challenges. 

The event was developed through the National Institute for Health Research Oxford Health Biomedical Research Centre (a partnership between the University of Oxford and the Oxford Health NHS Foundation Trust).

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

How Mindfulness May Improve Body Satisfaction and Mood

New research from Emma Osborne, Research Assistant at the Centre for Research on Eating Disorders (CREDO) at the University of Oxford (and PhD Candidate at the University of Bath), and Dr Melissa Atkinson, University of Bath, investigated two ways in which mindfulness might improve body satisfaction and mood.

Review Highlights Risk Factors Associated with Violence in Schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

New Study will Investigate Brain Fog Symptoms in Post-Hospitalised COVID-19 Patients

C-Fog is a collaborative new study led by Oxford University researcher, Dr Maxime Taquet, which will investigate the reasons why brain fog or cognition problems affect patients after COVID-19 infection. With a better understanding of the mechanisms involved it may be possible to understand how to treat brain fog and help many thousands of people worldwide.

A New Experimental Study Investigated the Effects of Atorvastatin on Emotional Processing

Atorvastatin is one of a group of statins widely used to treat heart and blood vessel diseases. The medication works by lowering cholesterol in the blood. This new study shows that atorvastatin influences the way people experience certain emotions, giving us important insights about disorders such as anxiety and depression.

Joy - Exhibition at the Wellcome Collection: until 27 February 2022

Morten Kringelbach, Professor of Neuroscience, University of Oxford, contributed expert insight about the relationship between pleasure and emotional and physical health in the context of artwork in the current Joy Exhibition.

People with Long-COVID After Hospitalisation Face Limited Recovery After One Year

People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge, according to the latest results of a major national study looking at the long-term health impacts of COVID-19 on hospitalised patients.